메뉴 건너뛰기




Volumn 2, Issue 5, 2010, Pages 705-718

Use of antiplatelet therapies during primary percutaneous coronary intervention for acute myocardial infarction

Author keywords

acute myocardial infarction; antiplatelet therapy; aspirin; cilostazol; clopidogrel; glycoprotein IIb IIIa blockers; prasugrel; primary percutaneous coronary intervention; ticagrelor

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CANGRELOR; CARDIOVASCULAR AGENT; CLOPIDOGREL; ELINOGREL; EPTIFIBATIDE; HIRULOG; PLACEBO; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; STREPTOKINASE; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG;

EID: 78349279641     PISSN: 17555302     EISSN: 17555310     Source Type: Journal    
DOI: 10.2217/ica.10.57     Document Type: Review
Times cited : (1)

References (79)
  • 2
    • 0035902456 scopus 로고    scopus 로고
    • Current concepts of the pathogenesis of the acute coronary syndrome
    • Libby P: Current concepts of the pathogenesis of the acute coronary syndrome. Circulation 104, 365-372 (2001).
    • (2001) Circulation , vol.104 , pp. 365-372
    • Libby, P.1
  • 3
    • 35448971466 scopus 로고    scopus 로고
    • on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the redefnition of myocardial infarction: Universal defnition of myocardial infarction
    • Thygessen K, Alpert JS, White HD; on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the redefnition of myocardial infarction: Universal defnition of myocardial infarction. Eur. Heart J. 28, 2525-2538 (2007).
    • (2007) Eur. Heart J. , vol.28 , pp. 2525-2538
    • Thygessen, K.1    Alpert, J.S.2    White, H.D.3
  • 4
    • 57349189353 scopus 로고    scopus 로고
    • Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology
    • Van de Werf F, Bax J, Betriu A et al.: Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur. Heart J. 29, 2909-2945 (2008).
    • (2008) Eur. Heart J. , vol.29 , pp. 2909-2945
    • Van De Werf, F.1    Bax, J.2    Betriu, A.3
  • 5
    • 68849107287 scopus 로고    scopus 로고
    • Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction
    • Rabbani LE, Iyengar S, Dangas GD et al.: Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction. J. Interv. Cardiol. 22, 378-384 (2009).
    • (2009) J. Interv. Cardiol. , vol.22 , pp. 378-384
    • Rabbani, L.E.1    Iyengar, S.2    Dangas, G.D.3
  • 6
    • 70449514842 scopus 로고    scopus 로고
    • Coronary microembolization: From bedside to bench and back to bedside
    • Heusch G, Kleinbongard P, Böse D et al.: Coronary microembolization: from bedside to bench and back to bedside. Circulation 120, 1822-1836 (2009).
    • (2009) Circulation , vol.120 , pp. 1822-1836
    • Heusch, G.1    Kleinbongard, P.2    Böse, D.3
  • 7
    • 65249135889 scopus 로고    scopus 로고
    • Incidence and clinical consequences of distal embolization on the coronary angiogram after percutaneous coronary intervention for ST-elevation myocardial infarction
    • Fokkema ML, Vlaar PJ, Svilaas T et al.: Incidence and clinical consequences of distal embolization on the coronary angiogram after percutaneous coronary intervention for ST-elevation myocardial infarction. Eur. Heart J. 30, 908-915 (2009).
    • (2009) Eur. Heart J. , vol.30 , pp. 908-915
    • Fokkema, M.L.1    Vlaar, P.J.2    Svilaas, T.3
  • 9
    • 0023805341 scopus 로고
    • Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
    • ISIS-2 (Second International Study of Infarct Survival) Collaborative Group
    • Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 349, 349-360 (1988).
    • (1988) Lancet , vol.349 , pp. 349-360
  • 10
    • 9144270451 scopus 로고    scopus 로고
    • Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology
    • Patrono C, Bachmann F, Baigent C et al.: Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur. Heart J. 25, 166-181 (2004).
    • (2004) Eur. Heart J. , vol.25 , pp. 166-181
    • Patrono, C.1    Bachmann, F.2    Baigent, C.3
  • 11
    • 77956164467 scopus 로고    scopus 로고
    • A randomized comparison of a clopidogrel high loading and maintenance dose regimen versus standard dose and high versus low dose aspirin in 25,000 patients with acute coronary syndromes: Results of the CURRENT OASIS 7 Trial
    • Presented at: Barcelona, Spain, 29 August-2 September
    • Mehta SR, Van de Werf F: A randomized comparison of a clopidogrel high loading and maintenance dose regimen versus standard dose and high versus low dose aspirin in 25,000 patients with acute coronary syndromes: results of the CURRENT OASIS 7 Trial. Presented at: Congress of the European Society of Cardiology. Barcelona, Spain, 29 August-2 September, 2009.
    • (2009) Congress of the European Society of Cardiology
    • Mehta, S.R.1    Van De Werf, F.2
  • 12
    • 33747874088 scopus 로고    scopus 로고
    • A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: The ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Infammation and Ongoing Necrosis) trial
    • Montalescot G, Sideris G, Meuleman C et al.: A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Infammation and Ongoing Necrosis) trial. J. Am. Coll. Cardiol. 48, 931-938 (2006).
    • (2006) J. Am. Coll. Cardiol. , vol.48 , pp. 931-938
    • Montalescot, G.1    Sideris, G.2    Meuleman, C.3
  • 13
    • 24644495673 scopus 로고    scopus 로고
    • Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fbrinolytics: The PCI-CLARITY study
    • Sabatine MS, Cannon CP, Gibson CM et al.: Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fbrinolytics: the PCI-CLARITY study. JAMA 294, 1224-1232 (2005).
    • (2005) JAMA , vol.294 , pp. 1224-1232
    • Sabatine, M.S.1    Cannon, C.P.2    Gibson, C.M.3
  • 14
    • 33750901162 scopus 로고    scopus 로고
    • Acute Coronary Syndromes (ACOS) registry investigators. Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice
    • Zeymer U, Gitt AK, Junger C et al.: Acute Coronary Syndromes (ACOS) registry investigators. Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice. Eur. Heart J. 27, 2661-2666 (2006).
    • (2006) Eur. Heart J. , vol.27 , pp. 2661-2666
    • Zeymer, U.1    Gitt, A.K.2    Junger, C.3
  • 15
    • 0035908781 scopus 로고    scopus 로고
    • Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study
    • Mehta SR, Yusuf S, Peters RJ et al.: Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358, 527-533 (2001).
    • (2001) Lancet , vol.358 , pp. 527-533
    • Mehta, S.R.1    Yusuf, S.2    Peters, R.J.3
  • 16
    • 0037145863 scopus 로고    scopus 로고
    • Clopidogrel for the reduction of events during observation: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention a randomized controlled trial
    • Steinhubl SR, Berger PB, Mann JT III et al.: Clopidogrel for the reduction of events during observation: early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention a randomized controlled trial. JAMA 288, 2411-2420 (2002).
    • (2002) JAMA , vol.288 , pp. 2411-2420
    • Steinhubl, S.R.1    Berger, P.B.2    Mann Iii, J.T.3
  • 17
    • 67849083515 scopus 로고    scopus 로고
    • Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction
    • Fefer P, Hod H, Hammerman H et al.: Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction. Am. J. Cardiol. 104, 514-518 (2009).
    • (2009) Am. J. Cardiol. , vol.104 , pp. 514-518
    • Fefer, P.1    Hod, H.2    Hammerman, H.3
  • 18
    • 56949093392 scopus 로고    scopus 로고
    • Design and rationale of CURRENT-OASIS 7: A randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy
    • Mehta SR, Bassand JP, Chrolavicius S et al.: Design and rationale of CURRENT-OASIS 7: a randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am. Heart J. 156, 1080-1088 (2008).
    • (2008) Am. Heart J. , vol.156 , pp. 1080-1088
    • Mehta, S.R.1    Bassand, J.P.2    Chrolavicius, S.3
  • 19
    • 53449098101 scopus 로고    scopus 로고
    • Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: The Reload with Clopidogrel before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study
    • Collet JP, Silvain J, Landivier A et al.: Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study. Circulation 118, 1225-1233 (2008).
    • (2008) Circulation , vol.118 , pp. 1225-1233
    • Collet, J.P.1    Silvain, J.2    Landivier, A.3
  • 20
    • 27744516843 scopus 로고    scopus 로고
    • Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial
    • Von Beckerath N, Taubert D, Pogatsa-Murray G et al.: Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112, 2946-2950 (2005).
    • (2005) Circulation , vol.112 , pp. 2946-2950
    • Von Beckerath, N.1    Taubert, D.2    Pogatsa-Murray, G.3
  • 21
    • 37349111065 scopus 로고    scopus 로고
    • Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial
    • Wiviott SD, Trenk D, Frelinger AL et al.: Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116, 2923-2932 (2007).
    • (2007) Circulation , vol.116 , pp. 2923-2932
    • Wiviott, S.D.1    Trenk, D.2    Frelinger, A.L.3
  • 22
    • 74249088972 scopus 로고    scopus 로고
    • Prasugrel compared with high-dose clopidogrel in acute coronary syndrome
    • Montalescot G, Sideris G, Cohen R et al.: Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. Thromb. Haemost. 103, 213-223 (2010).
    • (2010) Thromb. Haemost. , vol.103 , pp. 213-223
    • Montalescot, G.1    Sideris, G.2    Cohen, R.3
  • 23
    • 67651173161 scopus 로고    scopus 로고
    • Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial
    • Michelson AD, Frelinger AL III, Braunwald E et al.: Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur. Heart J. 30, 1753-1763 (2009).
    • (2009) Eur. Heart J. , vol.30 , pp. 1753-1763
    • Michelson, A.D.1    Frelinger Iii, A.L.2    Braunwald, E.3
  • 25
    • 55949103494 scopus 로고    scopus 로고
    • Greater clinical beneft of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel - Thrombolysis in Myocardial Infarction 38
    • Wiviott SD, Braunwald E, Angiolillo DJ et al.: Greater clinical beneft of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel - Thrombolysis in Myocardial Infarction 38. Circulation 118, 1626-1636 (2008).
    • (2008) Circulation , vol.118 , pp. 1626-1636
    • Wiviott, S.D.1    Braunwald, E.2    Angiolillo, D.J.3
  • 26
    • 60649112469 scopus 로고    scopus 로고
    • Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomised controlled trial. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomised controlled trial
    • Montalescot G, Wiviott SD, Braunwald E et al.: Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373, 723-731 (2009).
    • (2009) Lancet , vol.373 , pp. 723-731
    • Montalescot, G.1    Wiviott, S.D.2    Braunwald, E.3
  • 27
    • 70450199115 scopus 로고    scopus 로고
    • 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the
    • American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
    • Kushner FG, Hand M, Smith SC Jr et al.: 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 54, 2205-2241 (2009).
    • (2009) J. Am. Coll. Cardiol. , vol.54 , pp. 2205-2241
    • Kushner, F.G.1    Hand, M.2    Smith Jr., S.C.3
  • 28
    • 73949112820 scopus 로고    scopus 로고
    • Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study
    • Gurbel PA, Bliden KP, Butler K et al.: Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120, 2577-2585 (2009).
    • (2009) Circulation , vol.120 , pp. 2577-2585
    • Gurbel, P.A.1    Bliden, K.P.2    Butler, K.3
  • 29
    • 70149101223 scopus 로고    scopus 로고
    • Ticagrelor versus clopidogrel in patients with acute coronary syndromes
    • Wallentin L, Becker RC, Budaj A et al.: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045-1057 (2009).
    • (2009) N. Engl. J. Med. , vol.361 , pp. 1045-1057
    • Wallentin, L.1    Becker, R.C.2    Budaj, A.3
  • 31
    • 33344464928 scopus 로고    scopus 로고
    • Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, Phase II, multicenter, randomized, placebo- and active-controlled trial
    • E1-689. E10 2006
    • Greenbaum AB, Grines CL, Bittl JA et al.: Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, Phase II, multicenter, randomized, placebo- and active-controlled trial. Am. Heart J. 151, 689. E1-689.E10 (2006).
    • Am. Heart J. , vol.151 , pp. 689
    • Greenbaum, A.B.1    Grines, C.L.2    Bittl, J.A.3
  • 32
    • 71849087338 scopus 로고    scopus 로고
    • Platelet inhibition with cangrelor in patients undergoing PCI
    • Harrington RA, Stone GW, McNulty S et al.: Platelet inhibition with cangrelor in patients undergoing PCI. N. Engl. J. Med. 361, 2318-2329 (2009).
    • (2009) N. Engl. J. Med. , vol.361 , pp. 2318-2329
    • Harrington, R.A.1    Stone, G.W.2    McNulty, S.3
  • 33
    • 67650761110 scopus 로고    scopus 로고
    • Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
    • Chen KY, Rha SW, Li YJ et al.: Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 119, 3207-3214 (2009).
    • (2009) Circulation , vol.119 , pp. 3207-3214
    • Chen, K.Y.1    Rha, S.W.2    Li, Y.J.3
  • 34
    • 62949165644 scopus 로고    scopus 로고
    • Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: A randomized, controlled study
    • Han Y, Li Y, Wang S et al.: Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am. Heart J. 157, 733-739 (2009).
    • (2009) Am. Heart J. , vol.157 , pp. 733-739
    • Han, Y.1    Li, Y.2    Wang, S.3
  • 35
    • 44349138210 scopus 로고    scopus 로고
    • Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention
    • Biondi-Zoccai GG, Lotrionte M, Anselmino M et al.: Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am. Heart J. 155, 1081-1089 (2008).
    • (2008) Am. Heart J. , vol.155 , pp. 1081-1089
    • Biondi-Zoccai, G.G.1    Lotrionte, M.2    Anselmino, M.3
  • 36
    • 60749114799 scopus 로고    scopus 로고
    • Interindividual variability in the response to oral antiplatelet drugs: A position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology
    • Kuliczkowski W, Witkowski A, Polonski L et al.: Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur. Heart J. 30, 426-435 (2009).
    • (2009) Eur. Heart J. , vol.30 , pp. 426-435
    • Kuliczkowski, W.1    Witkowski, A.2    Polonski, L.3
  • 37
    • 34447576539 scopus 로고    scopus 로고
    • Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis
    • Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV: Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am. Heart J. 154, 221-231 (2007).
    • (2007) Am. Heart J. , vol.154 , pp. 221-231
    • Snoep, J.D.1    Hovens, M.M.2    Eikenboom, J.C.3    Van Der Bom, J.G.4    Jukema, J.W.5    Huisman, M.V.6
  • 38
    • 34447503098 scopus 로고    scopus 로고
    • Association of laboratory-defned aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta-analysis
    • Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV: Association of laboratory-defned aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch. Intern. Med. 167, 1593-1599 (2007).
    • (2007) Arch. Intern. Med. , vol.167 , pp. 1593-1599
    • Snoep, J.D.1    Hovens, M.M.2    Eikenboom, J.C.3    Van Der Bom, J.G.4    Huisman, M.V.5
  • 39
    • 35348816934 scopus 로고    scopus 로고
    • Anti platelet therapy after implantation of drug-eluting stents: Duration, resistance, alternatives, and management of surgical patients
    • Gurbel PA, DiChiara J, Tantry US: Anti platelet therapy after implantation of drug-eluting stents: duration, resistance, alternatives, and management of surgical patients. Am. J. Cardiol. 100(8B), M18-M25 (2007).
    • (2007) Am. J. Cardiol. , vol.100 , Issue.8 B
    • Gurbel, P.A.1    Dichiara, J.2    Tantry, U.S.3
  • 40
    • 77952075376 scopus 로고    scopus 로고
    • Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis
    • Sof F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF: Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb. Haemost. 103, 841-848 (2010).
    • (2010) Thromb. Haemost. , vol.103 , pp. 841-848
    • Sof, F.1    Marcucci, R.2    Gori, A.M.3    Giusti, B.4    Abbate, R.5    Gensini, G.F.6
  • 41
    • 41249093357 scopus 로고    scopus 로고
    • Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study
    • Bonello L, Camoin-Jau L, Arques S et al.: Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J. Am. Coll. Cardiol. 51, 1404-1411 (2008).
    • (2008) J. Am. Coll. Cardiol. , vol.51 , pp. 1404-1411
    • Bonello, L.1    Camoin-Jau, L.2    Arques, S.3
  • 42
    • 77149139817 scopus 로고    scopus 로고
    • High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients
    • Tavassoli N, Voisin S, Carrie D et al.: High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients. Am. J. Cardiovasc. Drugs 10, 29-35 (2010).
    • (2010) Am. J. Cardiovasc. Drugs , vol.10 , pp. 29-35
    • Tavassoli, N.1    Voisin, S.2    Carrie, D.3
  • 43
    • 58249135635 scopus 로고    scopus 로고
    • Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study
    • Collet JP, Hulot JS, Pena A et al.: Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373, 309-317 (2009).
    • (2009) Lancet , vol.373 , pp. 309-317
    • Collet, J.P.1    Hulot, J.S.2    Pena, A.3
  • 44
    • 58749090547 scopus 로고    scopus 로고
    • Genetic determinants of response to clopidogrel and cardiovascular events
    • Simon T, Verstuyft C, Mary-Krause M et al.: Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363-375 (2009).
    • (2009) N. Engl. J. Med. , vol.360 , pp. 363-375
    • Simon, T.1    Verstuyft, C.2    Mary-Krause, M.3
  • 45
    • 58749094444 scopus 로고    scopus 로고
    • Cytochrome p-450 polymorphisms and response to clopidogrel
    • Mega JL, Close SL, Wiviott SD et al.: Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354-362 (2008).
    • (2008) N. Engl. J. Med. , vol.360 , pp. 354-362
    • Mega, J.L.1    Close, S.L.2    Wiviott, S.D.3
  • 46
    • 79957472412 scopus 로고    scopus 로고
    • Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: A meta-analysis
    • DOI: 10.1038/tpj.2010.21 Epub ahead of print
    • Sof F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF: Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J. DOI: 10.1038/tpj.2010.21 (2010) (Epub ahead of print).
    • (2010) Pharmacogenomics J.
    • Sof, F.1    Giusti, B.2    Marcucci, R.3    Gori, A.M.4    Abbate, R.5    Gensini, G.F.6
  • 47
    • 77949894946 scopus 로고    scopus 로고
    • Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis
    • Giusti B, Gori AM, Marcucci R, Abbate R. Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis. Expert. Opin. Drug Metab. Toxicol. 6, 393-407 (2010).
    • (2010) Expert. Opin. Drug Metab. Toxicol. , vol.6 , pp. 393-407
    • Giusti, B.1    Gori, A.M.2    Marcucci, R.3    Abbate, R.4
  • 48
    • 66349133650 scopus 로고    scopus 로고
    • Cytochrome P450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes
    • Mega JL, Close SL, Wiviott SD et al.: Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119, 2553-2560 (2009).
    • (2009) Circulation , vol.119 , pp. 2553-2560
    • Mega, J.L.1    Close, S.L.2    Wiviott, S.D.3
  • 49
    • 77950508416 scopus 로고    scopus 로고
    • Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies
    • The RESPOND Study
    • Gurbel PA, Bliden KP, Butler K et al.: Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies. The RESPOND Study. Circulation 121, 1188-1199 (2010).
    • (2010) Circulation , vol.121 , pp. 1188-1199
    • Gurbel, P.A.1    Bliden, K.P.2    Butler, K.3
  • 50
    • 73149118496 scopus 로고    scopus 로고
    • The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: Frst experience in patients
    • Gurbel PA, Bliden KP, Antonino MJ et al.: The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: frst experience in patients. J. Thromb. Haemost. 8, 43-53 (2010).
    • (2010) J. Thromb. Haemost. , vol.8 , pp. 43-53
    • Gurbel, P.A.1    Bliden, K.P.2    Antonino, M.J.3
  • 51
    • 62549101321 scopus 로고    scopus 로고
    • Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients with Clopidogrel Resistance) randomized study
    • Jeong YH, Lee SW, Choi BR et al.: Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J. Am. Coll. Cardiol. 53, 1101-1109 (2009).
    • (2009) J. Am. Coll. Cardiol. , vol.53 , pp. 1101-1109
    • Jeong, Y.H.1    Lee, S.W.2    Choi, B.R.3
  • 52
    • 73549106603 scopus 로고    scopus 로고
    • Evaluation of platelet inhibition by tirofban in patients stratifed according to aspirin and clopidogrel responsiveness: The 3T/2R (tailoring treatment with tirofban in patients showing resistance to aspirin and/or resistance to clopidogrel)
    • Campo G, Valgimigli M, Frangione A et al.: Evaluation of platelet inhibition by tirofban in patients stratifed according to aspirin and clopidogrel responsiveness: the 3T/2R (tailoring treatment with tirofban in patients showing resistance to aspirin and/or resistance to clopidogrel). J. Am. Coll. Cardiol. 55, 255-256 (2010).
    • (2010) J. Am. Coll. Cardiol. , vol.55 , pp. 255-256
    • Campo, G.1    Valgimigli, M.2    Frangione, A.3
  • 53
    • 0034624841 scopus 로고    scopus 로고
    • Microvascular dysfunction in acute myocardial infarction: Focus on the roles of platelet and infammatory mediators in the no-refow phenomenon
    • Michaels AD, Gibson CM, Baron HV: Microvascular dysfunction in acute myocardial infarction: focus on the roles of platelet and infammatory mediators in the no-refow phenomenon. Am. J. Cardiol. 85, B50-B60 (2000).
    • (2000) Am. J. Cardiol. , vol.85
    • Michaels, A.D.1    Gibson, C.M.2    Baron, H.V.3
  • 54
    • 10644269830 scopus 로고    scopus 로고
    • Effcacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: A meta-analysis of randomized, controlled trials
    • de Queiroz Fernandes Araujo JO, Veloso HH, Braga De Paiva JM et al.: Effcacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials. Am. Heart J. 148, 937-943 (2004).
    • (2004) Am. Heart J. , vol.148 , pp. 937-943
    • De Queiroz Fernandes Araujo, J.O.1    Veloso, H.H.2    Braga De Paiva, J.M.3
  • 55
    • 16444368352 scopus 로고    scopus 로고
    • Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: A meta-analysis of randomized trials
    • De Luca G, Suryapranata H, Stone GW et al.: Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 293, 1759-1765 (2005).
    • (2005) JAMA , vol.293 , pp. 1759-1765
    • De Luca, G.1    Suryapranata, H.2    Stone, G.W.3
  • 56
    • 34548359246 scopus 로고    scopus 로고
    • Abciximab in primary coronary stenting of ST-elevation myocardial infarction: A European meta-analysis on individual patients' data with long-term follow-up
    • Montalescot G, Antoniucci D, Kastrati A et al.: Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur. Heart J. 28, 443-449 (2007).
    • (2007) Eur. Heart J. , vol.28 , pp. 443-449
    • Montalescot, G.1    Antoniucci, D.2    Kastrati, A.3
  • 57
    • 0032566404 scopus 로고    scopus 로고
    • Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction
    • ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators
    • Brener SJ, Barr LA, Burchenal JE et al.: Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 98, 734-741 (1998).
    • (1998) Circulation , vol.98 , pp. 734-741
    • Brener, S.J.1    Barr, L.A.2    Burchenal, J.E.3
  • 59
    • 19244387281 scopus 로고    scopus 로고
    • Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction
    • Neumann FJ, Kastrati A, Schmitt C et al.: Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J. Am. Coll. Cardiol. 35, 915-921 (2000).
    • (2000) J. Am. Coll. Cardiol. , vol.35 , pp. 915-921
    • Neumann, F.J.1    Kastrati, A.2    Schmitt, C.3
  • 60
    • 0141765874 scopus 로고    scopus 로고
    • Benefts and risks of abciximab use in primary angioplasty for acute myocardial infarction: The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial
    • Tcheng JE, Kandzari DE, Grines CL et al.: Benefts and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 108, 1316-1323 (2003).
    • (2003) Circulation , vol.108 , pp. 1316-1323
    • Tcheng, J.E.1    Kandzari, D.E.2    Grines, C.L.3
  • 61
    • 4444384038 scopus 로고    scopus 로고
    • Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: A prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone
    • Antoniucci D, Migliorini A, Parodi G et al.: Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation 109, 1704-1706 (2004).
    • (2004) Circulation , vol.109 , pp. 1704-1706
    • Antoniucci, D.1    Migliorini, A.2    Parodi, G.3
  • 62
    • 65549139808 scopus 로고    scopus 로고
    • Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading. A randomized double-blind trial
    • Mehilli J, Kastrati A, Schulz S et al.: Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading. A randomized double-blind trial. Circulation 119, 1933-1940 (2009).
    • (2009) Circulation , vol.119 , pp. 1933-1940
    • Mehilli, J.1    Kastrati, A.2    Schulz, S.3
  • 63
    • 70349630641 scopus 로고    scopus 로고
    • Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
    • Mehran R, Lansky AJ, Witzenbichler B et al.: Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 374, 1149-1159 (2009).
    • (2009) Lancet , vol.374 , pp. 1149-1159
    • Mehran, R.1    Lansky, A.J.2    Witzenbichler, B.3
  • 64
    • 67650925419 scopus 로고    scopus 로고
    • Infuence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality
    • Witkowski A, Maciejewski P, Wasek W et al.: Infuence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality Eur. Heart J. 30, 1736-1743 (2009).
    • (2009) Eur. Heart J. , vol.30 , pp. 1736-1743
    • Witkowski, A.1    MacIejewski, P.2    Wasek, W.3
  • 65
    • 72949090599 scopus 로고    scopus 로고
    • Risk profle and benefts from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: A meta-regression analysis of randomized trials
    • De Luca G, Navarese E, Marino P. Risk profle and benefts from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur. Heart J. 30, 2705-2713 (2009).
    • (2009) Eur. Heart J. , vol.30 , pp. 2705-2713
    • De Luca, G.1    Navarese, E.2    Marino, P.3
  • 66
    • 77951719621 scopus 로고    scopus 로고
    • Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting
    • Jeremias A, Vasu S, Gruberg L, Kastrati A, Stone GW, Brown DL: Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting. Catheter. Cardiovasc. Interv. 75, 895-902 (2010).
    • (2010) Catheter. Cardiovasc. Interv. , vol.75 , pp. 895-902
    • Jeremias, A.1    Vasu, S.2    Gruberg, L.3    Kastrati, A.4    Stone, G.W.5    Brown, D.L.6
  • 67
    • 44249120546 scopus 로고    scopus 로고
    • Facilitated PCI in patients with ST-elevation myocardial infarction
    • Ellis SG, Tendera M, de Belder MA et al.: Facilitated PCI in patients with ST-elevation myocardial infarction. N. Engl. J. Med. 358, 2205-2217 (2008).
    • (2008) N. Engl. J. Med. , vol.358 , pp. 2205-2217
    • Ellis, S.G.1    Tendera, M.2    De Belder, M.A.3
  • 68
    • 75149170908 scopus 로고    scopus 로고
    • Primary percutaneous coronary angioplasty with and without eptifbatide in ST-segment elevation myocardial infarction: A safety and effcacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST)
    • Le May MR, Wells GA, Glover CA et al.: Primary percutaneous coronary angioplasty with and without eptifbatide in ST-segment elevation myocardial infarction: a safety and effcacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST). Circ. Cardiovasc. Interv. 2, 330-338 (2009).
    • (2009) Circ. Cardiovasc. Interv. , vol.2 , pp. 330-338
    • Le May, M.R.1    Wells, G.A.2    Glover, C.A.3
  • 69
    • 49149128492 scopus 로고    scopus 로고
    • Prehospital initiation of tirofban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): A multicentre, double-blind, randomised controlled trial
    • Van't Hof AW, Ten BJ, Heestermans T et al. Prehospital initiation of tirofban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet. 372, 537-546, 2008).
    • (2008) Lancet , vol.372 , pp. 537-546
    • Van'T Hof, A.W.1    Ten, B.J.2    Heestermans, T.3
  • 70
    • 38349188423 scopus 로고    scopus 로고
    • The relative safety and effcacy of abciximab and eptifbatide in patients undergoing primary percutaneous coronary intervention: Insights from a large regional registry of contemporary percutaneous coronary intervention
    • Gurm HS, Smith DE, Collins JS et al.: The relative safety and effcacy of abciximab and eptifbatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention. J. Am. Coll. Cardiol. 51, 529-535 (2008).
    • (2008) J. Am. Coll. Cardiol. , vol.51 , pp. 529-535
    • Gurm, H.S.1    Smith, D.E.2    Collins, J.S.3
  • 71
    • 42249090036 scopus 로고    scopus 로고
    • Comparison of angioplasty with infusion of tirofban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: The MULTISTRATEGY randomized trial
    • Valgimigli M, Campo G, Percoco G et al.: Comparison of angioplasty with infusion of tirofban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 299, 1788-1799 (2008).
    • (2008) JAMA , vol.299 , pp. 1788-1799
    • Valgimigli, M.1    Campo, G.2    Percoco, G.3
  • 72
    • 61349143698 scopus 로고    scopus 로고
    • Left ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofban (from the Facilitated Angioplasty with Tirofban or Abciximab [FATA] Trial)
    • Taglieri N, Saia F, Guiducci V et al.: Left ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofban (from the Facilitated Angioplasty with Tirofban or Abciximab [FATA] Trial). Am. J. Cardiol. 103, 785-790 (2009).
    • (2009) Am. J. Cardiol. , vol.103 , pp. 785-790
    • Taglieri, N.1    Saia, F.2    Guiducci, V.3
  • 73
    • 70450141566 scopus 로고    scopus 로고
    • A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: A meta-analysis of contemporary randomized controlled trials
    • Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER: A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials. Circ. Cardiovasc. Interv. 2, 230-236 (2009)
    • (2009) Circ. Cardiovasc. Interv. , vol.2 , pp. 230-236
    • Gurm, H.S.1    Tamhane, U.2    Meier, P.3    Grossman, P.M.4    Chetcuti, S.5    Bates, E.R.6
  • 74
    • 50949102097 scopus 로고    scopus 로고
    • Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: The randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial
    • Thiele H, Schindler K, Friedenberger J et al.: Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 118, 49-57 (2008).
    • (2008) Circulation , vol.118 , pp. 49-57
    • Thiele, H.1    Schindler, K.2    Friedenberger, J.3
  • 75
    • 70349417896 scopus 로고    scopus 로고
    • Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention-effects on soluble CD40 ligand concentrations
    • Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P et al.: Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention-effects on soluble CD40 ligand concentrations. Atherosclerosis 206, 523-527 (2009).
    • (2009) Atherosclerosis , vol.206 , pp. 523-527
    • Dominguez-Rodriguez, A.1    Abreu-Gonzalez, P.2    Avanzas, P.3
  • 76
    • 70449686719 scopus 로고    scopus 로고
    • Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: Rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration
    • Gu YL, Fokkema ML, Kampinga MA et al.: Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration. Trials 10, 90 (2009).
    • (2009) Trials , vol.10 , pp. 90
    • Gu, Y.L.1    Fokkema, M.L.2    Kampinga, M.A.3
  • 77
    • 77953281484 scopus 로고    scopus 로고
    • A multicenter randomized study to evaluate intracoronary abciximab with the ClearWay catheter to improve outcomes with Lysis (IC ClearLy): Trial study design and rationale
    • Sardella G, Sangiorgi GM, Mancone M et al.: A multicenter randomized study to evaluate intracoronary abciximab with the ClearWay catheter to improve outcomes with Lysis (IC ClearLy): trial study design and rationale. J. Cardiovasc. Med. 11, 529-535 (2010).
    • (2010) J. Cardiovasc. Med. , vol.11 , pp. 529-535
    • Sardella, G.1    Sangiorgi, G.M.2    Mancone, M.3
  • 78
    • 77149179733 scopus 로고    scopus 로고
    • Intracoronary Eptifbatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: The Intracoronary Eptifbatide (ICE) trial
    • Deibele AJ, Jennings LK, Tcheng JE, Neva C, Earhart AD, Gibson CM: Intracoronary Eptifbatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifbatide (ICE) trial. Circulation 121, 784-791 (2010).
    • (2010) Circulation , vol.121 , pp. 784-791
    • Deibele, A.J.1    Jennings, L.K.2    Tcheng, J.E.3    Neva, C.4    Earhart, A.D.5    Gibson, C.M.6
  • 79
    • 52749095514 scopus 로고    scopus 로고
    • Effect of intracoronary tirofban in patients undergoing percutaneous coronary intervention for acute coronary syndrome
    • Wu TG, Zhao Q, Huang WG et al.: Effect of intracoronary tirofban in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Circ. J. 72, 1605-1609 (2008).
    • (2008) Circ. J. , vol.72 , pp. 1605-1609
    • Wu, T.G.1    Zhao, Q.2    Huang, W.G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.